The COVID‐19 Host Genetics Initiative gathered researchers from around the world in a quest to better understand and treat COVID‐19 infections {#ajmga61244-sec-0001}
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Ever since its 2019 outbreak in Wuhan, China, coronavirus disease 2019 (COVID‐19) has been rapidly and relentlessly circling the globe, attaining pandemic status according to the World Health Organization only three months after it was first identified. As of this writing, the Johns Hopkins University of Medicine Coronavirus Resource Center\'s online case tracker reports more than 12 million confirmed cases of COVID‐19 globally; more than half a million people have died from the virus. Moreover, there is a dearth of specific drugs or treatments to manage or prevent COVID‐19 infection.

Many people who are infected with COVID‐19 seem to experience mild or moderate symptoms that only require supportive care, or they appear to be asymptomatic. However, data show that COVID‐19 can have a range of effects: patients with the most severe symptoms tend to be older and/or have multiple underlying conditions, such as hypertension, diabetes, cancer, obesity, and/ or a compromised immune system. Yet, numerous young and seemingly healthy individuals have developed serious complications from the virus and then succumbed to the infection.

It has become increasingly clear that the variability among patients\' responses to COVID‐19 goes beyond age or the presence of a comorbid condition, as there appears to be a great deal of heterogeneity in terms of symptoms, severity, and recovery time. In addition to nongenetic factors, some of these differences could be related to genetic factors in those affected---and this is the impetus behind the COVID‐19 Host Genetics Initiative.
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The idea for the COVID‐19 Host Genetics Initiative grew from a series of discussions between Mark Daly, PhD, a geneticist and the director of the Institute for Molecular Medicine in Helsinki, Finland, and his colleague Andrea Ganna, PhD, a group leader at the same institution, regarding several potential genetic studies that they were planning to conduct in Finland and Northern Italy. This was back in March when the virus had reached pandemic status and, as Dr. Daly explains, "We quickly realized that in order for the study of host genetics to reach a global scale and impact, we would need to short‐circuit the 'normal' human genetics process in which groups work individually for a long time and only years later come together to perform the larger, more defi nitive genetic analyses." He notes that, "given the urgency of the outbreak in Europe at that time, and soon after in the Americas and elsewhere, the past decade of human genetics experience led us to think that we could perhaps within months move towards a global analysis."

On March 16, Dr. Ganna announced, via Twitter, the launch of the COVID‐19 Host Genetics Initiative. He stated that the initiative\'s goal would be to "aggregate genetic and clinical information on individuals affected by COVID‐19." The response from the scientifi c community was "remarkable," says Dr. Daly, with activity quickly building to include more than 1,000 participating scientists from more than 200 research institutes or hospitals worldwide. Since then, "a great deal of work has taken place to discuss broadly applicable defi nitions of susceptibility and severity across different types of studies," he reports. "In the past few days, we have just released publicly results from the fi rst well‐powered consortium metaanalyses of severity and susceptibility, immediately upon completion, to allow them to be used by all."

The COVID‐19 Host Genetics Initiative is a self‐described "bottom‐up collaborative effort" that includes 3 primary goals: 1) provide an environment to foster the sharing of resources to facilitate COVID‐19 host genetics research; 2) organize analytical activities across studies to identify genetic determinants of COVID‐19 susceptibility and severity; and 3) provide a platform so that these activities can be shared, along with individual‐level data where possible (Eur J Hum Genet, [2020](#ajmga61244-bib-0001){ref-type="ref"}).

"It has been extremely gratifying to see how many in the community have rallied to work together and share data openly in order to achieve the most informative genetic study," says Dr. Daly. "There is much more to come as the summer moves forward."
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Data resources include retrospective collections, which are typically biobanks containing signifi cant genetic data and active connections to health systems. These offer the opportunity to rapidly develop a genetic study on susceptibility and severity. Another resource are prospective studies, which will bring important additional opportunities for deeper DNA analyses and potentially informative viral and antibody profi ling and epitope mapping experiments.

The primary analysis focuses on COVID‐19 disease severity and, given the challenges in defi ning severity across multiple studies and health care systems,a pragmatic approach is used, one that considers the use of invasive and noninvasive ventilation as an index of severity. Bioinformatic and statistical analysis will consider data generated from a genomewide association study array, and exome and genome sequencing, leveraging the impact of both common and rare variants. Key analyses will take into account differences between sexes, ancestries, and date of sample collection.

It is expected that a large portion of the studies will have the capacity to share individual‐level data, and genetic/genomic and clinical data are submitted to the European Genome‐phenome Archive (EGA) under controlled access. Most of the planning, discussion, and exchange of information among the participants is conducted on a dedicated Slack workspace with the support of the International Common Disease Alliance.

"We are using a relatively simple genetic approach," explains Dr. Ganna. "The main goal is to improve the connection between researchers, to get the maximum analysis from the sample size." Although the effort does not have huge implications from a clinical standpoint, he notes that it could help better understand and dissect the pandemic (in combination with other data) and "might have some predictive power." Notably, the information amassed from this initiative will help to understand the biology of the disease and may help to answer epidemiological questions.

The COVID‐19 Host Genetics Initiative is expected to be ongoing as its collaborators seek to gain a far better understanding of viral variability, susceptibility, severity, and outcomes. Hopefully, a clearer picture of the underlying genetics will emerge within the near future.
